Oncogenic proteins as tumor antigens

Current Opinion in Immunology

Volumn 8, Issue 5, 1996, Pages 637-642

  Disis, Mary L ^a   Cheever, Martin A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CARCINOGENESIS; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; IMMUNITY; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; TUMOR IMMUNITY;

EID: 0030272816     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80079-3     Document Type: Article

References (42)

1. + cytotoxic T cells. Cancer Res. 53:1993;3257-3261.
2. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52:1992;4168-4174.
3. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52:1992;6380-6384.
4. Houbiers JG, Van-der-Burg SH, Van-de-Watering LM, Tollenaar RA, Brand A, Van-de-Velve CJ, Melief CJ. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer. 72:1995;637-641.
5. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T. Serum p53 antibodies as early markers of lung cancer. of outstanding interest Nat Med. 1:1995;701-702 A detailed report of the p53 antibody response detected in two heavy smokers who had no evidence of malignancy at the time of the initial antibody determination. Subsequently, the patients developed p53 lung cancers. This study suggests the use of an antibody response to p53 as potential cancer diagnostic and candidate biomarker of lung cancer.
6. Green JA, Mudenda B, Jenkins J, Leinster SJ, Tarunina M, Green B, Robertson L. Serum p53 auto-antibodies: incidence in familial breast cancer. Eur J Cancer. 5:1994;580-584.
7. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M, et al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. of special interest Eur J Immunol. 25:1995;1765-1769 Three breast cancer patients were identified who had the mutated p53 gene in their tumor and accumulated p53 protein. These patients also had an antibody response specific for p53. Analysis of the T cell response in these individuals revealed proliferation in response to wild-type p53. This study provides evidence of the importance of the role of immune recognition of self epitopes even in mutated cancer-specific oncoproteins.
8. Noguchi Y, Richards EC, Chen YT, Old LI. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA. 92:1995;2219-2223.
9. Nijman HW, Van-der-Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol Lett. 40:1994;171-178.
10. Ropke M, Regner M, Claesson MH. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand J Immunol. 42:1995;98-103.
11. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. of outstanding interest Proc Natl Acad Sci USA. 92:1995;11993-11997 Investigations outlining a novel technique for the determination of antigenic epitopes. HLA-A2-transgenic mice were immunized with putative A2-binding peptides and peptide-specific CTLs were easily generated. These were then tested against a panel of p53-expressing HLA-matched targets. This is a unique system for defining potential human epitopes that may be biologically relevant.
12. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Quin HL, Takahashi M, Chen W. Immunity to oncogenic proteins. Immunol Rev. 145:1995;33-59.
13. + T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur J Immunol. 25:1995;2588-2597.
14. Fenton RG, Keller CJ, Hanna N, Taub DD. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichie coll. J Natl Cancer Inst. 87:1995;1853-1861.
15. Takahashi M, Chen W, Byrd D, Disis ML, Huseby E, McCahill L, Nelson H, Peace D, Quin HL, Shimada H, et al. Antibody responses to ras proteins in patients with colon cancer. Clin Cancer Res. 1:1995;1071-1077.
16. + T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int J Cancer. 56:1994;40-45.
17. Fossum B, Breivik J, Meling GI, Gedde-Dahl T III, Hansen T, Knutsen I, Rognum TO, Thorsby E, Gaudemack G. A K-ras 13Gly→Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int J Cancer. 58:1994;506-511.
18. + T cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res. 55:1995;2984-2987.
19. *0201. Int J Cancer. 61:1995;389-396.
20. + T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immonother. 40:1995;165-172.
21. Abrams SI, Horan P, Tsang KY, Schlom J. Mutant Ras epitopes as targets for cancer vaccines. of outstanding interest Semin Oncol. 23:1996;118-134 Excellent overview of the preclinical studies leading up to human clinical trials of a Ras-based vaccine for the treatment of malignancy.
22. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl T III, Stokke KT, Solheim BG, Egge TS, Soreide O, Thorsby E, Gaudemack G. Ex vivo Ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer. 65:1995;450-453.
23. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O, Thorsby E, Geudernack G. Vaccination with mutant Ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. of outstanding interest Lancet. 346:1995;1399-1400 One of the first reports of immunization with a Ras-peptide-based vaccine in humans. Describes a vaccine stragegy of infusing large amounts of Ras-peptide-loaded APCs into patients with pancreatic cancer. No toxicity was associated with the regimen and Ras-specific T cell responses were induced in two out of five patients treated.
24. bcr-abl protein. Proc Natl Acad Sci USA. 89:1992;1468-1472.
25. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A. Specific binding of leukemia oncogene fusion protein peptides of HLA class I molecules. Blood. 85:1995;2680-2684.
26. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. of special interest Blood. 87:1996;3587-3592 After an extensive study of the binding of peptides derived from oncogenic fusion proteins to various HLA-types [25], the authors succeeded in generating peptide-specific T cells that were able to proliferate in response to and/or lyse peptide coated targets. The peptides were derived from the Bcr-Abl fusion protein. This study provides the foundation for the potential generation of leukemia-specific immunity of humans.
27. Ten-Bosch GJ, Toornvliet AC, Friede T, Melief CJ, Leeksma OC. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia. 9:1995;1344-1348.
28. Rabbitts TH. Chromosomal translocations in human cancer. Nature. 372:1994;143-149.
29. Nanda NK, Sercrz II. Induction of anti-self-immunity to cure cancer. of outstanding interest Cell. 82:1995;13-17 Comprehensive theoretical overview of the immune response to self cancer proteins. The review includes relevant references and discusses similarities in the study of autoimmunity and cancer immunity.
30. Fisk B, Blevins TL, Wharton JT, loannides CG. Identification of an immunodominat peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 181:1995;2109-2117.
31. Peoples GE, Geodegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA. 92:1995;432-436.
32. Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ. Shared T cell epitopes in epithelial tumors. Cell Immunol. 164:1995;279-286.
33. Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P, Greene MI. Prevention of breast tumour development in vivo by down regulation of the p185neu receptor. of outstanding interest Nat Med. 1:1995;644-648 These experiments define the therapeutic potential of antibody immunity directed against the HER-2/neu oncogen. HER-2/neu-transgenic animals treated with an antibody specific for the extracellular domain of the HER-2/neu protein were protected from the tumor development. The mechanism of the response was determined: interference with phophorylation of the HER-2/neu receptor kinase and cell signaling.
34. Carger P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepart HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:1992;4285-4289.
35. Weiner LM, Clark JI, Davey M, Li WS, Garcia-de-Plazzo I, Ring DB, Alpaugh RK. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:1995;4586-4593.
36. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, and oncogenic self-protein. of special interest J Immunol. 156:1996;3151-3158 Studies described wher validate the concept that subdominant epitopes in self proteins are available for immune recognition. Rats immunized with rat HER-2/neu do not develop HER-2/neu-specific immunity. When animals are immunized with peptides derived from the rat HER-2/neu protein structure both rat HER-2/neu antibody and T cell responses are generated. Peptide vaccines may be an effective vaccine strategy in immunizing to human 'self' cancer proteins.
37. + hematopoletic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55:1995;1099-1104.
38. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, IIdstad ST, Kast WM, Deleo AB, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. of special interest Nat Med. 1:1995;1297-1302 DCs pulsed with CTL peptides derived from sarcoma and lung carcinoma tumor models in mice are an effective vaccine. Not only did immunization with peptide-pulsed DCs protect animals from subsequent challenge with tumor, but the DC vaccine was effective in mediating an antitumor response in animals bearing existent macroscopic disease.
39. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 39:1994;127-138.
40. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 95:1995;1897-1905.
41. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. of special interest Nat Med. 1:1995;1179-1183 The authors recently identified a peptide derived from the connexin 37 gap junction protein that induces antitumor CTLs. Animals immunized with peptides were protected from the development of metastasis. Peptide vaccination was also associated with a reduction in tumor burden when animals with pre-existing disease were immunized. In this mode, peptide immunization was effectiove in the treatment of residual disease.
42. Ladd A, Walfield A, Tsong YY, Thau R. Active immunization against LHRH alone or combined with LHRH-analogue treatment impedes growth of androgen-dependent prostatic carcinoma. Am J Reprod Immunol. 34:1995;200-206.